Scientific articleOrchiectomy for advanced prostatic carcinoma A reevaluation☆
References (11)
- et al.
Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies
J. Urol.
(1960) - et al.
The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
Cancer Res.
(1941) - et al.
Endocrine control of prostatic carcinoma: clinical and statistical survey of 1,818 cases
J.A.M.A.
(1950) Treatment and survival of patients with cancer of the prostate
Surg. Gynec. Obstet.
(1967)Computation of survival rates
Nat. ancer Inst. Monogr.
(1964)
Cited by (103)
A cell kinetics model for prostate cancer and its application to clinical data and individual patients
2010, Journal of Theoretical BiologyCitation Excerpt :As shown in Fig. 9, the model results compare favorably with those of D’Amico et al. (2003a) and Freedland et al. (2005) using α=3×10−5 for GL<8, α=3×10−3 for GL≥8 and the critical cell populations listed in Table 3. With these values, the model can describe the clinical data with HT of Blackard et al. (1973) and Lau et al. (2002), as summarized in Table 5. However, to describe the results with CT of Armstrong et al. (2007), it is important to model the fact that the rate at which the toxins are taken up by the PC cells depends on their metabolic rate compared to that of normal cells.
Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms
2008, European UrologyCitation Excerpt :Of the men initially presenting with metastatic disease 85% will die of prostate cancer. The median survival of such men in older but representative studies is in the range of 2.5–3 yr [2]. These rates are dramatically more favourable if prostate cancer is diagnosed at an early stage.
The benefits of early androgen blockade
2008, Best Practice and Research: Clinical Endocrinology and MetabolismCitation Excerpt :Although many large-scale randomized trials conducted in the last half of the past century investigated the potential role of AB in asymptomatic stage-II and -V disease, this issue has still not been conclusively decided. The Veterans Administration Urological Research Group (VACURG) I and II trials attempted to establish the optimal timing of AB in men with asymptomatic advanced or metastatic disease, but several design flaws and errors in the execution of these studies compromised potentially valuable conclusions.19–21 The main criticisms of these studies include toxic treatments and non-adherence to study design.
Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective
2007, European Journal of Surgical OncologyClinical Strategies in the Management of Biochemical Recurrence after Radical Prostatectomy
2003, Clinical Prostate Cancer
- ☆
This study was made under grant R10 CA12443 from the National Cancer Institute, National Institutes of Health, Public Health Service.
- †
Members are listed on page 560.